talazoparib,enzalutamide
pfizer,Astellas
['talzenna', 'crpc', 'biomarker', 'xtandi', 'pfizer']
asco data bolster talzenna, xtandi benefit in hrr-mutant mcrpc as pfizer pursues allcomers approval. biomarker-selected patients benefitted from the added parp inhibitor, but oncologists still don't know what to think about the benefit in patients... 